6-Methoxytryptamine

6-Methoxytryptamine
Clinical data
Other names6-Methoxy-T; 6-MeO-T; PAL-263; PAL263
Drug classMonoamine releasing agent; Serotonin–norepinephrine–dopamine releasing agent; Serotonin receptor modulator
ATC code
  • None
Identifiers
  • 2-(6-methoxy-1H-indol-3-yl)ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.020.708 Edit this at Wikidata
Chemical and physical data
FormulaC11H14N2O
Molar mass190.246 g·mol−1
3D model (JSmol)
  • COC1=CC2=C(C=C1)C(=CN2)CCN
  • InChI=1S/C11H14N2O/c1-14-9-2-3-10-8(4-5-12)7-13-11(10)6-9/h2-3,6-7,13H,4-5,12H2,1H3
  • Key:VOCGEKMEZOPDFP-UHFFFAOYSA-N

6-Methoxytryptamine (6-MeO-T; developmental code name PAL-263) is a monoamine releasing agent and serotonin receptor modulator of the tryptamine family. It is a positional isomer of 5-methoxytryptamine.

Pharmacology

6-Methoxytryptamine is a potent serotonin–norepinephrine–dopamine releasing agent (SNDRA), with EC50Tooltip half-maximal effective concentration values for monoamine release induction of 53.8 nM for serotonin, 113 nM for dopamine, and 465 nM for norepinephrine in rat brain synaptosomes. It is also a full agonist of the serotonin 5-HT2A receptor, but with very low potency; its EC50 and EmaxTooltip maximal efficacy at this receptor were 2,443 nM and 111%, respectively. In a series of tryptamine derivatives, 6-methoxytryptamine was the least potent serotonin 5-HT2A receptor agonist, while 5-methoxytryptamine was the most potent serotonin 5-HT2A receptor agonist, with 5-methoxytryptamine showing approximately 4,857-fold higher potency in terms of serotonin 5-HT2A receptor agonism than 6-methoxytryptamine. Conversely, whereas 6-methoxytryptamine was a potent monoamine releasing agent, 5-methoxytryptamine showed very low potency in this regard.

History

6-Methoxytryptamine was first described in the scientific literature by the 1950s.

Derivatives

Certain β-carbolines and harmala alkaloids, such as harmine, harmaline, and tetrahydroharmine, are notable in being naturally occurring cyclized tryptamine derivatives of 6-methoxytryptamine. The same is true of certain iboga alkaloids, such as tabernanthine and ibogaline. Tabernanthalog (DLX-007) is a synthetic simplified ibogalog analogue of tabernanthine that is under development for use as a potential pharmaceutical drug in the treatment of neuropsychiatric disorders.

See also